Abstract:Background:Familial glucocorticoid deficiency (FGD) is a rare autosomal recessive disease characterized by glucocorticoid deficiency without mineralocorticoid deficiency. We report 3 Chinese patients with MRAP or MC2R mutations.Case Reports:Patient 1 presented with hyperpigmentation. Endocrine investigations revealed low serum cortisol levels and elevated adrenocorticotropic hormone (ACTH) levels. Furthermore, low serum sodium was evident. She was diagnosed with FGD type 2 due to a homozygous mutation in MRAP (c.106+1delG), revealed through exome sequencing (ES). After 2-year treatment with hydrocortisone, skin hyperpigmentation was improved. Patient 2 initially presented with hyponatremia. Low cortisol levels and high levels of ACTH were subsequently detected; he was subjected to a hydrocortisone treatment during which he experienced repeated hypoglycemic attacks and pigmentation. ES revealed the same mutation as in patient 1 in MRAP (c.106+1delG), thus he was diagnosed with FGD type 2. After 6 years of age, his symptoms remarkably improved, and there was no episode of hypoglycemia. Patient 3 mainly presented with hyperpigmentation, hypoglycemic attack, and tall stature. Laboratory findings were normal except for low serum cortisol levels and high ACTH levels. She was diagnosed with FGD type 1 as ES revealed a novel homozygous mutation in MC2R (c.712C>A, p.His238Tyr). After nearly 2 years of hydrocortisone replacement therapy, the excessive growth was reduced to near normal, and the skin color returned to normal.Conclusions:Three patients were diagnosed with FGD (one with FGD type 1 and two with FGD type 2). They all presented with hyperpigmentation and hypoglycemia; however, compared with patient 1, the clinical manifestations of patient 2 were more complicated. Patient 3 had later onset and taller stature than patients 1 and 2. A novel mutation in patient 3 expands the mutation spectrum of MC2R.

Obesity due to proopiomelanocortin deficiency: three new cases and treatment trials with thyroid hormone and ACTH4-10

Several Mutations in the Melanocortin 4 Receptor Gene Are Associated with Obesity in Chinese Children and Adolescents

Cardiac Phenotype and Tissue Sodium Content in Adolescents With Defects in the Melanocortin System

Melanocortin 4 Receptor Pathway Dysfunction in Obesity: Patient Stratification Aimed at MC4R Agonist Treatment

A Melanocortin-4 Receptor Agonist Induces Skin and Hair Pigmentation in Patients with Monogenic Mutations in the Leptin-Melanocortin Pathway

Could setmelanotide be the game-changer for acquired hypothalamic obesity?

Early-set POMC methylation variability is accompanied by increased risk for obesity and is addressable by MC4R agonist treatment

Desacetyl-α-melanocyte stimulating hormone and α-melanocyte stimulating hormone are required to regulate energy balance

A novel melanocortin 4 receptor (MC4R) gene mutation associated with morbid obesity

Hypothalamic ER–associated Degradation Regulates POMC Maturation, Feeding, and Age-Associated Obesity

Pro-opiomelanocortin Gene Transfer to the Nucleus of the Solitary Track but Not Arcuate Nucleus Ameliorates Chronic Diet-Induced Obesity

Pro‐opiomelanocortin Gene Delivery into the Nucleus Tractus Solitarius Ameliorates Obesity and is Characterized by Unabated Anorexia

Melanocortin Activation of Nucleus of the Solitary Tract Avoids Anorectic Tachyphylaxis and Induces Prolonged Weight Loss.

MC4R agonism promotes durable weight loss in patients with leptin receptor deficiency

A Novel Mutation in Melanocortin Receptor 2 and a Reported Mutation in Melanocortin Receptor 2 Accessory Protein: Three Chinese Cases with Familial Glucocorticoid Deficiency.

Homozygous null mutation of the melanocortin-4 receptor and severe early-onset obesity

A novel missense mutation in the signal peptide of the human POMC gene: a possible additional link between early-onset type 2 diabetes and obesity

POMC overexpression in the ventral tegmental area ameliorates dietary obesity.

The Proopiomelanocortin System

Diagnostic and therapeutic odyssey of two patients with compound heterozygous leptin receptor deficiency

MC1R is Dispensable for the Proteinuria Reducing and Glomerular Protective Effect of Melanocortin Therapy